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In the past ten years, studies have shown the recognition of Trypanosoma cruzi-associated molecular patterns by members of the
Toll-like receptor (TLR) family and demonstrated the crucial participation of diﬀerent TLRs during the experimental infection
with this parasite. In the present review, we will focus on the role of TLR-activated pathways in the modulation of both innate and
acquired immune responses to T. cruzi infection, as well as discuss the state of the art of vaccine research and development against
the causative agent of Chagas disease (or American trypanosomiasis).
1.Introduction
Trypanosoma cruzi is an intracellular trypanosomatid pro-
tozoan, which is transmitted to the human host by blood-
feeding reduviid bugs, members of the insect subfamily Tri-
atominae. Other modes of transmission include oral infec-
tion through contaminated food, congenital transmission,
blood transfusions, organ transplants, and by accidental lab-
oratoryinoculation.Thisparasite,aswellasitsvectorandthe
disease it causes, was ﬁrst described by Chagas in 1909 [1].
Presently, the World Health Organization (WHO) estimates
that approximately 10 million people are infected [2]. While
Chagas disease is endemic to Central and South America, in
the last years infected individuals have also been registered
among immigrants in the United States, Europe, and Japan
[3]. Although most of these cases were imported from the
endemic regions, vector-transmitted autochthonous infec-
tions have also been documented in the United States. This
fact and the lack of mandatory screening for all blood and
tissue donors point to a possible altered epidemiology of
Chagas disease in a near future.
The determinants of Chagas disease come from the bur-
den and the lineage of the inoculated parasite, as well as the
infectionrouteandtheimmunecompetentstatusofthehost.
Two diﬀerent phases of the disease follow the entrance of T.
cruziintothehost(forareviewsee[4]).Theacutephaselasts
around two months and is asymptomatic in most infected
individuals although some patients can present symptoms
like prolonged fever, anorexia, nausea, vomiting, and diar-
rhea. During this phase, high numbers of parasites are fre-
quently found in the host bloodstream and tissues, as well as
high plasma levels of cytokines and intense activation of B
and T lymphocytes. Also, lymphoadenopathy, splenomegaly,
and intense inﬂammatory processes may be associated with
parasite nests within tissues. A small percentage (5–10%) of
infected individuals can develop a more severe condition,
presenting myocarditis or meningoencephalitis, which they
may die of. Most of the contaminated individuals remain
asymptomatic (indeterminate form) often for years or even
decades,but,then,around30%ofpatientsdevelopcardiacor
gastrointestinal complications, characteristics of the chronic2 Journal of Parasitology Research
phaseoftheChagasdisease.Thepathologicalbasisofchronic
chagasic cardiomyopathy (CCC) has been a matter of intense
debate for years. Immunopathology due to parasite persis-
tence is considered a key element in the development of CCC
although there is also evidence of a role for autoimmunity.
During the chronic phase (indeterminate or not) few or no
parasites are found in the circulation, but reactivation may
occur by immunosuppression, particularly AIDS, and by
pregnancy. The only eﬀective and approved drugs in the
treatmentof the acutephase, or of the reactivation of the dis-
ease,arenitrofuran(nifurtimox,Lampit)andnitroimidazole
(benznidazole, Rochagan), which are not fully satisfactory
because of their limited eﬃcacy in the chronic stage and of
their important adverse side eﬀects. Host control of T. cruzi
has been shown to depend on both humoral and cell-med-
iated adaptive responses as well as on elements of the innate
immune system [5]. To date, however, no human vaccine
against infection with T. cruzi is currently available. Finally,
the economic and social burdens due to early morbidity and
mortality caused by Chagas disease are considerable, leading
to high economic losses in Latin America. Understanding of
the pathogenesis of Chagas disease will add to the develop-
ment of new molecular targets for prophylactic vaccines and
drug therapies, which are of extreme need for combating this
emerging neglected disease.
2.InnateImmunityandTLRs
For a long time innate responses were believed to be non-
speciﬁc to the invading pathogen. In contrast, acquired im-
munity mediated by T and B lymphocytes was shown to
display a ﬁne speciﬁcity for the diﬀerent pathogen-derived
antigens through the employment of clonal receptors, which
result from the genetic recombination of hundreds of diﬀer-
ent gene segments. The discovery in 1996 that the Drosophila
transmembrane protein Toll speciﬁcally mediates the recog-
nition and the response to fungal infection [6], followed
by the cloning of several related receptors in other species,
including human [7] and the discovery that one of these
molecules (TLR4) is the receptor for lipopolysaccharide
(LPS) [8], challenged the dogma that attributed nonspeci-
ﬁcity to innate immunity. Owing to the new receptors’ sim-
ilarity to the Drosophila Toll, these molecules were called
Toll-like receptors, or TLRs. So far, 10 and 12 diﬀerent func-
tional TLR-family members have been identiﬁed in man and
mice, respectively, of which TLRs 1–9 are conserved in both
species,TLR10isselectivelyexpressedinhumansandTLR11,
TLR12 and TLR13 are present in mice but not in humans
(reviewed in [9]). Each TLR recognizes diﬀerent chemical
structures, which are highly conserved in microorganisms
and collectively referred to as pathogen-associated molecular
patterns (PAMPs). Among these are lipids, carbohydrates,
nucleic acids, and various proteins derived from bacteria,
viruses, fungi, protozoa, and helminth parasites. Moreover,
TLR-signaling pathways may also be activated by self com-
ponents released by tissue damage or inﬂammation, the
so-called damage-associated molecular patterns (DAMPs),
which alert the immune system to danger resulting either
from sterile insult or from infection [10]. To learn the de-
tailed mechanisms by which the innate immune system de-
tects and responds to parasites is crucial to understanding
how infection is controlled. However, only recently insights
into how the TLR-signaling system responds to infection
by protozoans, including Trypanosoma cruzi, Trypanosoma
brucei, Leishmania spp., Plasmodium spp.a n dT o x o p l a s m a
gondii have emerged [11]. Diﬀerent TLRs show a diverse ex-
pression pattern in a variety of cells and tissues, as well as
diﬀerent subcellular localization (either on the cell surface
or within endosomal compartments). Although a certain
degree of redundancy exists between signals induced by the
various TLRs, recent studies have identiﬁed signaling path-
waysspeciﬁcforindividual TLRs,involving diﬀerent adaptor
molecules responsible for signal transduction. This leads to
cytokine release proﬁles speciﬁc for particular PAMPs, and,
thus,TLRsconferacertaindegreeofspeciﬁcitytotheinnate-
immune response. The formation of heterodimers among
diverse TLRs (as TLR2/TLR6 or TLR2/TLR1) or the employ-
ment of accessory molecules (as CD14 or CD36), for the
recognition of certain PAMPs but not others, creates a fur-
therdegreeofspeciﬁcity[12].Recognitionofmicrobialcom-
ponents by TLRs triggers the initial innate immune response
leading to inﬂammatory gene expression and, eventually,
to the clearance of the infectious agent. Moreover, TLR-med-
iated recognition, by inducing the maturation of dendritic
cells and, consequently, directing the T helper responses,
represents a link between the innate- and acquired-immune
systems [9]. Finally, as a result of studies searching for TLR
agonists and antagonists, as well as for inhibitors of TLR-
signaling pathways, drugs with these properties are currently
being tested in a variety of therapeutic applications, and at
least one TLR agonist (monophosphoryllipid A-MPL) has
already been approved as adjuvant in vaccines [13].
Other germline-encoded innate receptor families were
discovered in the last years and, together with TLRs, are col-
lectively called pattern-recognition receptors (PRRs). These
include membrane-bound C-type lectin receptors (CLRs),
cytosolic proteins such as nucleotide-binding oligomeriza-
tion domain (NOD)-like receptors (NLRs), and RIG-I-like
receptors (RLRs) (reviewed in [14]). Although TLRs play a
centralroleintheinitiationofimmuneresponsesagainstdif-
ferent pathogens, microbes display multiple PAMPs, which
activate both TLRs and other PRRs, becoming evident that
PRRs other than TLRs are also involved in the control of
innate immunity. Moreover, while TLR ligand speciﬁcity,
signalingpathways,andcellulartraﬃckinghavebeenbroadly
studied, less is known about the expected crosstalk between
diﬀerent PRR pathways, and the consequences that such an
interaction would have for the induction of eﬀective innate
and acquired immune responses.
As reviewed here, after infection with T. cruzi, several in-
ﬂammatory genes are activated through diﬀerent TLR path-
ways. This leads to inﬂammatory response and induction
of diverse eﬀector mechanism of the adaptive immune res-
ponse, which culminates with pathogen control, though the
sterile cure is not achieved. On the other hand, very little is
known about T. cruzi recognition by other PRRs. Recently,
the ﬁrst example of NLR-dependent response accounting forJournal of Parasitology Research 3
host resistance against infection with a protozoan has been
reported [15]. In this work, Nod1−/− mice were shown to be
very susceptible to T. cruzi, succumbing to the infection and
displaying higher parasitemia and parasite loads in the
spleen and heart tissues, although NOD1 deﬁciency does not
impairtheproductionofdiﬀerentcytokinesasIL-12,TNF-α,
IFN-γ, or IL-10. As T. cruzi parasites lack peptidoglycan or
any known agonist for NOD1, it would be interesting to
determine whether NOD1 directly senses a T. cruzi-derived
PAMP, or if the NOD1 pathway is indirectly activated during
infection. Therefore, the detailed mechanism by which
NOD1 confers resistance to infection with T. cruzi remains
to be described and a possible cross-talk between NLR and
TLR pathways during infection with T. cruzi waits for further
investigation.
3. TLR Agonists Expressedby T. cruzi
In the past years, diﬀerent groups have identiﬁed diverse
T. cruzi-derived molecules that act as TLR agonists, inducing
the production of nitric oxide (NO) and the secretion of in-
ﬂammatory cytokines and chemokines by cells of the mono-
cytic lineage. The ﬁrst major class of T. cruzi molecules to be
characterized as PAMPs was trypomastigote-derived glyco-
sylphosphatidylinositol (tGPI) anchors of mucin-like glyco-
proteins, which are distributed at the cell-surface membrane
of T. cruzi and were identiﬁed as potent activators of TLR2
from both mouse and human origin [16]. Proinﬂammatory
activity of tGPI was shown to be dependent on its ﬁne struc-
ture, mainly the unsaturated fatty acid at the sn-2 position
of the alkylacylglycerolipid component. In contrast, another
member of the GPI family puriﬁed from epimastigote forms,
named glycoinositolphospholipid (eGIPL) and whose lipid
moiety is instead composed by a N-lignoceroylsphinganine,
was shown to induce NF-κB activation via TLR4 [17]. GIPLs
arefreeanchorsabundantlypresentatthesurfacemembrane
of all parasite stage forms, presenting diﬀerent biological
eﬀects on diﬀerent cell types [18, 19]. Importantly, the struc-
tureofGIPLsdisplayedbytheinfectivemetacyclictrypomas-
tigote and by the epimastigote forms is very similar to each
other, containing the same conserved Man4-GlcN glycan
sequence and the myo-inositol-phosphate-lipid moiety pre-
dominantly (70%) formed by inositol-phosphoceramides,
although its constitution may change depending on the
T. cruzi strain [20]. For example, while GIPLs from Y, G, and
Tulahuen strains contain ceramide, those from the CL strain
are a mixture of dihydroceramide and alkylacylglycerol spe-
cies [21]. Therefore, the variable lipid moiety composition of
diﬀerent GPI anchors determines whether their recognition
is mediated by TLR2 (alkylacylglycerol) or TLR4 (dihydro-
ceramide). Although tGPI (TLR2 agonist) and eGIPL from Y
strain (TLR4 agonist) were not compared in the same assay
for their relative capacity of inducing proinﬂammatory res-
ponses on cells expressing normal levels of TLR2 and TLR4
molecules, results obtained with human TLR2-transfected
CHO cells, which also express endogenous levels of hamster
TLR4, suggested a 100-fold superior activity of tGPI anchors
[16]. An interesting point yet to be investigated is whether
these diﬀerent GPI anchors, which may be released by the
parasite by shedding [22] and whose inﬂammatory activity
depends on TLR2 or TLR4, present synergistic properties. Of
note, genome-wise prediction analysis revealed that approx-
imately 12% of T. cruzi genes possibly encode GPI-anchored
proteins, a number much higher than in previously studied
protozoa or mammalian species [23]. Moreover, the recent
large-scale analysis of GPI-anchored molecules identiﬁed 78
GIPLs and 11ptn-GPIs, of which 70GIPLs and 8ptn-GPIs
were not previously described [23]. Among these, probably
novel TLR2 and/or TLR4 agonists will be characterized.
Other diﬀerences between T. cruzi-derived GIPL and tGPI
anchors were determined concerning the participation of
coreceptor molecules on their recognition and the triggered
signaling pathway. For instance, while anti-CD14 antibodies
blocked the production of TNF-α by human macrophages
exposed to tGPI-mucin in vitro [24], neutrophil attraction to
the peritoneal cavity triggered by the injection of eGIPL was
maintained in CD14-deﬁcient mice, indicating that eGIPL is
recognized by TLR4 in a CD14-independent way (Bellio, M.,
unpublished results). Also, TNF-α and MIP-2 production
in response to GIPL was shown to be signiﬁcantly lower in
CD1d-deﬁcent mice (which lack NKT cells) when compared
to WT mice [25]. Although the exact mechanisms for the
observed response remain elusive, these results clearly impli-
cate CD1d-restricted NKT cells in an early ampliﬁcation step
of cytokine and chemokine production during the innate
response elicited by T. cruzi GIPL. Therefore, the in vivo
eﬀects of T. cruzi PAMPs deserve further investigation with
regard to their mode of recognition by, and action on, dif-
ferent cell types.
Infective T. cruzi trypomastigotes invade host cells using
at least two diﬀerent strategies, either by an active process re-
cruiting host-cell lysosomes to the area of parasite cell con-
tact or by an alternative pathway, in which the parasite
infects phagocytic cells through conventional phagocytosis/
endocytosis mechanism [26–29]. While the general current
view is that TLRs do not function directly as phagocytic re-
ceptors, studies have demonstrated that TLR signaling by
means of MyD88 can enhance phagosome acidiﬁcation and
function, the so-called phagosome maturation, which is re-
quired for eﬀective sterilization of its contents [30]. In accor-
dancetothat,wehavedemonstratedthatthelevelsofT.cruzi
internalizationbymacrophagesisnotaﬀectedinthreediﬀer-
ent TLR4-deﬁcient mouse strains (C3H/HeJ, C57BL/10ScN,
and Tlr4−/−), but TLR4 and parasite colocalize into acidic
compartments, and, as soon as 4h after infection, the per-
centageofTLR4-deﬁcientmacrophagesinfectedwithT.cruzi
is signiﬁcant higher when compared to WT cells, indicating
the existence of an early trypanosomicidal mechanism trig-
geredbyTLR4,whichwasalsoshowntobedependentonthe
production of NO and reactive oxygen species (ROS) [31].
On the other hand, it was reported that during the invasion
of T. cruzi, the activation of the Rab5-dependent phago-
cytic pathway is regulated by TLR2-dependent signals in
macrophages [32]. Still, to our knowledge, there are no other
studies on the participation of surface TLR pathways in the
entrance of trypomastigotes into the host cells.
An additional TLR2 agonist with adjuvant proper-
ties, the T. cruzi-released protein related to thiol-disulﬁde4 Journal of Parasitology Research
oxidoreductase family, called Tc52, was also described [33].
Surprisingly, however, despite the known T. cruzi-derived
TLR2 agonists, no diﬀerences in parasitemia or mortality
were noted following infection of mice genetically deﬁcient
inTLR2[34].Intriguingly,althoughTLR2expressionbyma-
crophages stimulated in vitro with trypomastigote-derived
GPI anchors appears to be essential for induction of IL-12,
TNF-αandNO[16],wheninfected,theTLR2-deﬁcientmice
mount a robust proinﬂammatory cytokine and NO produc-
tion by spleen cells, as well as higher serum levels of IFN-γ,
when compared to WT mice [34]. This suggests an immuno-
regulatory role for TLR2 during the infection, maybe due to
the action of TLR2 ligands on Tregs [35].
Interestingly,morerecently,T.cruzi-derivednucleicacids
havebeenalsoshowntoactasPAMPs.GenomicDNA,which
contains abundant oligodeoxynucleotide unmethylated CpG
motifs, and total RNA puriﬁed from T. cruzi promote host
cell activation via TLR9 and TLR7, respectively, stimulating
cytokine response from macrophages and dendritic cells
(DCs) [36–39]. Also, potential TLR7 ligands as guanosine-
or uridine-rich single-strand RNA sequences were found by
in silico analysis in the predicted parasite transcriptome [39].
Indeed, as discussed below, Tlr9−/− and Tlr7−/− mice were
showntobemoresusceptiblethanWTmicetoinfectionwith
the parasite [37, 39].
4. Resistance to Infection Conferred by
Different TLR Pathways
Directly testing the hypothesis that TLR triggering by the
above-described PAMPs is crucial for host resistance against
the infection is currently not possible, however, due to the
absence of T. cruzi strains lacking the expression of any of the
above-described TLR agonists. On the other hand, studying
the course of infection in mice genetically deﬁcient for dif-
ferentTLR-encodinggenes,evaluatingmortality,parasitemi-
a,andseveralparametersoftheinnate andacquiredimmune
responses have brought additional understanding of the im-
pact of the lack of TLR-mediated recognition of T. cruzi for
development of host susceptibility to the infection. In this
context, the critical involvement of TLRs in the host resis-
tance to T. cruzi was ﬁrstly highlighted in mice deﬁcient for
the MyD88 adaptor molecule, which is the main transducer
of multiple TLR-signaling pathways [34]. In fact, Myd88−/−
mice were shown to be highly susceptible to infection and
to display lower production of proinﬂammatory cytokines,
including IL-12p40 and IFN-γ, from innate immune cells
[34] .I na c c o r d a n c e ,w eﬁ r s tr e p o r t e dt h a tC 3 H / H e Jm i c e ,
which express a nonfunctional natural mutant of TLR4, are
highlysusceptibletoinfectionwithT.cruzi[17],asevidenced
by a higher parasitemia and earlier mortality. However, since
classical genetic studies previously established that the re-
sistance to T. cruzi is governed by multiple genetic factors,
including H-2-linked genes [40, 41], the level of protection
given by the TLR4 pathway during the infection of C3H/HeJ
mice (whose C3H background is classiﬁed as “susceptible”)
could not be directly compared to the degree of susceptibil-
ity of infected Myd88−/− mice, which are of the resistant
C57BL/6 genetic background. Therefore, we further investi-
gated the impact of TLR4 deﬁciency in the Tlr4−/− (B6 back-
ground) mice [31]. We demonstrated that TLR4 signaling
triggers an important early parasiticidal event against T.
cruzi, which is dependent on the formation of NO and ROS
and that splenocytes of Tlr4−/− infected mice display lower
production of the proinﬂammatory cytokines IFN-γ and
TNF-α,a sw e l la so fN O ,w h e nc o m p a r e dt oW TB 6m i c e ,
what would explain the observed higher parasitemia levels
in TLR4-deﬁcient mice [31]. Together these results indicate
that TLR4, as previously shown for TLR2 and TLR9, also
contributes to resistance during the acute phase of infection
in B6 mice. TLR4 deﬁciency by itself, however, does not lead
to an earlier mortality in the B6 background [31].
An interesting study has demonstrated the involvement
of TLR9 in the protection against T. cruzi infection [37].
TLR9 is one of the members of the TLR family located at the
endolysosomal subcellular compartment and can recognize
parasite-derived DNA sequences [38]. More importantly,
since Tlr2−/−Tlr9−/− double knockouts display higher par-
asitemia than the single Tlr2−/− or Tlr9−/− mice, this work
wastheﬁrsttodemonstratethatTLR2andTLR9cancooper-
ate,and/or that a degree ofredundancy exist among diﬀerent
TLR family members, in the control of parasite replication.
Nevertheless, although attaining parasitemia levels compara-
bletotheobservedintheMyd88−/− strain(whichlackmulti-
ple TLR signaling), Tlr2−/−Tlr9−/− double deﬁcient mice did
not show the acute mortality exhibited by Myd88−/− mice.
This observation suggested that other TLR/IL-1R family
members, in addition to TLR2 and TLR9, could be involved
in the pathogenesis of T. cruzi infection. Furthermore, mice
lacking both MyD88 and a second adaptor molecule which
acts downstream TLR3 and TLR4, called TRIF, were shown
to be even more susceptible than Myd88−/− mice. Contrary
to Myd88−/−, the Myd88−/−Trif−/− double deﬁcient mice
were not able to control parasite levels in the bloodstream
and die at an earlier time point after infection [42]. The
TRIF-dependent pathway is indispensable for the induction
of type 1 IFNs through TLR3 and TLR4, but the role of type
1 IFNs in the resistance to infection with T. cruzi is con-
troversial [43, 44]. Curiously, although mice single deﬁcient
in TRIF or IFNAR1 (type 1 IFN receptor) were shown to be
resistant to the infection with T. cruzi, Myd88−/−Ifnar1−/−
double deﬁcient mice display the same highly suscepti-
ble phenotype as Myd88−/−Trif−/− double deﬁcient strain,
pointing to a protective role for IFN-β and/or IFN-α that,
however, only becomes apparent when the Myd88 pathway is
absent [42]. Therefore, the high sensitivity demonstrated by
the Myd88−/−Trif−/− double deﬁcient mice to infection is in
accordancewitharoleforTLR4and/orTLR3intheresponse
against T. cruzi, as these members of the TLR family are the
only known to use TRIF as a transducer molecule.
A very recent work studying Tlr3−/− mice, however, has
not supported any role for TLR3 in promoting control of T.
cruzi parasitemia or host survival [39]. Yet, the possibility
exists that a putative function of TLR3 would only become
apparent in the concomitant absence of other TLR-fam-
ily member with redundant function, by analogy to what
was previously observed for TLR2, whose involvement inJournal of Parasitology Research 5
protectionagainsttheparasitewasonlyevidentinthedouble
Tlr2−/−Tlr9−/− strain [37]. The article also provided, for the
ﬁrst time, evidences that TLR7 is a critical innate immune
receptor involved in the recognition of T.cruzi RNA and in
host resistance to a protozoan infection [39]. Caetano and
collaborators analyzed the course of infection in diﬀerent
mouse strains lacking one or multiple endolysosomal TLRs.
First, the authors followed the response to infection in a
strain of mice called 3d, which has a loss-of-function point
mutationinUNC93B1(anendoplasmicreticulum(ER)resi-
dent protein that mediates the translocation of the nucleo-
tide-sensing TLRs from the ER to the endolysosomes) and,
consequently, is unresponsive to TLR3, TLR7 and TLR9
ligands (TLR8 is believed to be biologically inactive in mice).
The phenotype of 3d mice was shown to be equivalent of the
triple deﬁcient Tlr3−/−Tlr7−/−Tlr9−/− strain and was inter-
mediary between Myd88−/− (highly susceptible) and Tlr9−/−
(moderately susceptible). This result suggested the contri-
bution of TLR7, besides TLR9, for the resistance against T.
cruzi, since, as mentioned, Tlr3−/− mice were not susceptible
to the infection. In fact, Tlr7−/− mice were shown to display
a degree of susceptibility comparable to Tlr9−/− mice [39].
Collectively, to date, the analysis of diﬀerent mice strains
lacking one or multiple TLR pathways demonstrated that
TLR2, TLR4, TLR7, and TLR9 play a role in the resistance
to infection with T. cruzi, with a degree of redundancy be-
tweenthem.Thedirectcomparisonbetweenthelevelsofsus-
ceptibility displayed by the diverse TLR-deﬁcient strains of
mice is not always possible though, due to the fact that the
abo v e-citedstudiesemplo y eddiﬀerentstrainsoftheparasite,
as Y [31, 34, 37], Tulahu´ en [42], or CL-Brener [39] strains,
each of them presenting diﬀerent virulence, tissue tropism,
and time course of parasitemia, and which may also express
PAMPs with diﬀerent ﬁne structures or levels of expression.
Nevertheless, important issues have been revealed in those
studies concerning the role of TLRs in innate and acquired
immunity against T. cruzi, as discussed below.
5.TLRs inthe InnateandAcquiredResponses
to T. cruzi
In the ﬁrst 7 to 10 days following infection, before acquired
immunity is fully activated, innate responses play a key role
incontainingparasitemia,throughtheactionofmicrobicidal
mediators (reactive nitrogen intermediates—RNI and ROS),
whose production is enhanced by the action of proinﬂam-
matory cytokines (IL-12, TNF-α,a n dI F N - γ) released by
macrophages, natural killer (NK), and γδ T cells [45, 46].
Then, acquired immunity mediated by the T-helper 1 (Th1)
cell response becomes crucial in parasitemia control and
host survival. The release of IFN-γ by Th1 CD4+ cells in-
duces the activation of phagocytic cells for parasite killing.
Th1 lymphocytes also provide help for the appropriate pro-
duction of antibodies (cytophilic and complement-ﬁxing
immunoglobulin G2a) and for cytotoxic CD8+T cells. The
geneticabsence,ortheexperimentalblocking,ofanyofthese
adaptive responses (antibodies, CD4+ or CD8+ cells) results
in uncontrolled parasite levels and decease [47–49]. Despite
the control of parasite burden by diﬀerent eﬀector responses,
however, its elimination is not achieved, leading to chroniﬁ-
cation of the infection. It is plausible that parasite persistence
results from suppression of microbicidal immunity by anti-
inﬂammatoryresponsesmediatedbyIL-10andtransforming
growth factor-β (TGF-β), as well as by inﬁltrating myeloid
cells with suppressor activity, which succeed and counteract
the potent inﬂammatory response that, otherwise, would
lead to life-threatening injury to organs [50, 51].
It is a current paradigm that the activation of dendritic
cells and other innate cells by TLR pathways is required for
and play a role in the modulation of acquired responses al-
though the precise function of each member of the TLR fam-
ily in the responses against T. cruzi is still to be fully deter-
mined. All the strains of mice with single or multiple TLR
deﬁciency tested to date, which display higher susceptibility
to infection with T. cruzi, were found to display lower proin-
ﬂammatory cytokine levels early during infection although
the degree of susceptibility varies between the diﬀerent TLR
knockouts, as discussed above. Accordingly, serum levels of
IFN-γ and IL-12 are low in MyD88−/− infected mice, as well
as the in vitro production of IFN-γ, IL-12, TNF-α and NO
by splenocytes obtained from these mice at day 10 postinfec-
tion[34].SimilarresultswereobtainedwithTlr4−/−,Tlr9−/−,
double Tlr2−/−Tlr9−/−, 3d, or Tlr7−/− mice [31, 37, 39].
Theseresultsconﬁrmedothersobtainedinvitro,wherelower
levels of IL-12 (or NO) and higher number of trypomastig-
otes were released by splenocytes (or by in vitro infected
macrophages) of MyD88-, double MyD88/TRIF-, TLR4-, 3d,
TLR9-, or TLR7-deﬁcient infected mice [31, 37, 39, 42].
Thus, with the apparent exception of TLR2, several TLRs
contribute in vivo to the induction of proinﬂammatory cyto-
kine secretion by infected host cells.
Beyond TLR’s roles in modulation of innate immunity,
the current paradigm strongly argues in favor of a critical
role of these receptors in shaping the adaptive immune res-
ponse [9]. This can be achieved mainly by their action on
antigen-presenting cells (APCs), either by promoting cross-
presentation for CD8 T-cell activation or by increasing the
levels of costimulatory molecules and by stimulating the sec-
retion of lineage-speciﬁc cytokines as IL-12, IL-6, IL-1β,I L -
18, and IL-23 by APCs and, thus, promoting Th1 and Th17
diﬀerentiation. Although initially controversial, diﬀerent
groups demonstrated the expression of TLRs on activated
T cells, as well as the eﬀects of TLR agonists functioning as
direct costimulatory signals during the initiation of the
adaptive immune response or as an aid in the survival of
memory T cells [35]. Therefore, one cannot rule out a direct
role for T. cruzi-derived PAMPs on T-cell activation and sur-
vival during the infection, although to date, evidence favor
the hypothesis that the major function of TLRs on T-cell
activation during infection is an indirect one.
Presently, data on the detailed role of TLRs in the acti-
vation of acquired immunity during infection with T. cruzi
are still scarce. Nonetheless, it was ﬁrst demonstrated that
CD4+ TcellsobtainedfrominfectedTlr9−/−,Tlr2−/−Tlr9−/−,
or MyD88−/− mice strains produced lower IFN-γ when stim-
ulatedinvitrobyinfectedsyngeneicBMDC[37],whileCD4+
T cells from infected TLR2-deﬁcient mice display levels of6 Journal of Parasitology Research
IFN-γ comparable to WT, as expected due to their resistant
phenotype [34]. Of note, the percentage of CD4+ IFN-γ+ T
cells in the spleen of infected MyD88−/− mice at day 11 and
13 postinfection were shown to be signiﬁcantly lower com-
paredtoWTmice,whereasthepercentageofCD4+ IFN-γ+ T
lymphocytes in the spleen of the Tlr4−/− strain resulted sim-
ilar to that found in WT mice, in accordance with the rela-
tively higher resistance of this strain, when compared to the
other mentioned TLR-deﬁcient mice [31]. Interestingly, the
same picture of low CD4+ T-cell activation was obtained
when analyzing the IFN-γ production by CD4+ Tl y m p h o -
cytesobtainedfrominfected3dorTlr3,7,9−/− tripledeﬁcient
mice, even when stimulated in vitro with antigen-pulsed WT
DCs, suggesting the lower frequency of activated CD4+ T
cells in infected spleens of these susceptible strains [39]. In
the particular case of MyD88−/− mice, the lower percentage
of Th1 cells could also be due to nonresponsiveness to IL-
18, since the receptor for this cytokine also relies on MyD88
for signaling, but the fact that mice deﬁcient in IL-18 are
not more susceptible to experimental infection with T. cruzi
[52] argues against this hypothesis. Therefore,in all the TLR-
deﬁcient strains tested, susceptibility to infection correlates
with lower levels of serum IL-12 and decreased frequency of
activated Th1 cells in the spleen.
A nonexpected result was found, in contrast, when the
percentage of CD8+ IFN-γ+ T cells (measured either by cyto-
m e t r yo rb yE L I S P O T ) ,a n dt h eC D 8 - d e p e n d e n tin vivo
cytotoxic activity was measured in Tlr2−/−,T l r 4 −/−,T l r 9 −/−,
and in MyD88−/− infected mice, as both parameters were
preserved to WT levels in all the above-cited deﬁcient strains
[31]. More recently, the maintenance of the frequency of
CD8+ T cells speciﬁc for an immunodominant peptide to
WTlevelshasbeenalsodemonstratedinMyD88−/−,Tlr9 −/−,
and 3d mice [39] although in vitro the levels of IFN-γ secre-
tion were lower in cell cultures of MyD88−/− and 3d, but
not of Tlr9−/− mice. A ﬁrst possible interpretation of these
results is that none of the tested TLR pathways is essential for
thegenerationofcytotoxicCD8+ TcellsduringT.cruziinfec-
tion. Of note, the TLR3- and TLR4-triggered TRIF pathway
is preserved in Myd88−/− mice, hence, their activation would
lead to type I IFN secretion and consequent DC maturation,
resulting in the normal CD8+ T-cell response observed in
these mice. Also in accordance with this hypothesis, exten-
sively discussed by us in a previous work [31], doubly
MyD88/TRIF-deﬁcient (as MyD88/IFNAR1 DKO) mice are
more sensitive to infection and do not control parasitemia
[42]. Alternatively, other signaling molecules and innate rec-
ognition systems can be involved in the generation of CD8+
T-cell responses. For example, it was described that NFATc1
activation and IFN-γ production in a TLR-independent
pathwaymayleadtoDCmaturationduringT.cruziinfection
[53]. Also, DC maturation may be induced by bradykinin
B2 receptors (B2Rs) after the release of pro-inﬂammatory
bradykinin peptidebytheparasiteproteasesduringinfection
[54]. Thirdly, a recent work, cited above, has demonstrated
the activation of NOD receptors by T. cruzi infection [15]
though it is still not clear whether these two latter pathways
would function independently of TLRs for licensing CD8+
T-cell eﬀector functions.
Therefore, the lower levels of CD4+ eﬀectors observed in
infected MyD88- or TLR-deﬁcient mice seem suﬃcient for
their help to CD8+ T cells but might not be enough for in-
ducing the necessary B-cell-mediated response, or for CD8+
T lymphocyte mobilization to parasite-infected tissue other
than spleen, as heart or liver, for example. Although a recent
report that described a role for IL-17A in host protection
against acute infection [55]a n dar o l ef o rT h 1 7c e l l si nr e g -
ulating parasite-induced myocarditis has been shown during
T. cruzi infection in mice [56], nothing is known at the
present time about the possible modulation of this T helper
subset, and its consequences to infection with T. cruzi,i n
the absence of TLR signaling. Undoubtedly, more work is
necessary for a full understanding of the eﬀects of T. cruzi-
induced TLR signaling in the control of adaptive immunity
against the parasite.
In summary, the present data support the idea that a
degree of redundancy exists among diﬀerent TLR family
members,meaningthateachoftheTLRpathwaysmaynotbe
individually essential for the resistance to infection. T. cruzi
displays various ligands for diﬀerent TLRs (see Figure 1)a n d
only the concomitant absence of signaling through multiple
TLR receptors, but not their individual deﬁciency, results in
a high degree of susceptibility to the infection.
No discussion about the role of TLRs in the infection by
T. cruzi could be complete without some speculation con-
cerning the possibility that the immunological response
elicited through TLR pathways might have a role in the prog-
ression of the disease toward its chronic phase, CCC. Both
T. cruzi- and heart tissue-speciﬁc responses have been put in
evidence and may be important for the pathology of CCC
although a consensus does not exist about the relative con-
tribution of each of these responses for CCC [57]. Whatever
the answer to this question might be, TLR signaling could be
impliedintheprocess,sincebesidetheirroleinthetriggering
of the adaptive response to pathogens, as above discussed,
several studies have also reported the contribution of TLR-
family members in the induction of autoimmunity [58].
However, studies on the chronic stage of infection with T.
cruzi are diﬃcult in mice of C57BL/6 genetic background (as
all the available TLR knockout strains), due to the scarcity of
good experimental models capable of inducing in these mice
thepathophysiologictraitsobservedinthehumancondition.
Notwithstanding, a study of 169 patients with chronic cha-
gasic cardiomyopathy and 76 T. cruzi-infected asymptomatic
individuals revealed that T. cruzi-infected patients who are
heterozygous for the MAL/TIRAP S180L variant (which
leads to a decrease in signal transduction upon ligation of
TLR2 or TLR4 to their respective ligand) may have a lower
risk of developing CCC [59]. Interestingly, it was also dem-
onstrated that TLR2 functions as the main upstream regu-
lator of hypertrophy triggered in isolated murine cardiomy-
ocytes by T. cruzi [60]. Therefore, the study of the involve-
mentofTLRsignalinginexperimentalmodelsofthechronic
phase of the Chagas’ disease could be of considerable value
in elucidating the pathophysiology of CCC, which remains
one of the major causes of heart failure among younger
individuals in Latin America today. Moreover, determining
preciselyhowTLR-TRIF-MyD88activationcouldtriggerandJournal of Parasitology Research 7
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Figure 1: T. cruzi-derived PAMPs are recognized by diﬀerent TLRs. The recognition of diﬀerent T. cruzi molecules, like parasite surface
glycoconjugates and nucleic acids, occurs through distinct Toll-like receptors, which are localized at the cellular plasma or endoplasmic
membranes, respectively, and are diﬀerentially expressed by various innate immune cell types. GPI anchors of mucin-like glycoproteins
activate TLR2/TLR6 heterodimer, GIPL is an agonist for TLR4, genomic DNA activates endosomal TLR9, and TLR7 is involved in parasite
RNA recognition. TLRs induce NF-κB and/or IRFs activation via their interaction with diﬀerent TIR domain-containing adaptor molecules.
Of these, MyD88 and Mal/TIRAP are required for TLR2 and TLR4 activation of NF-κB. In a MyD88-independent way, TRIF and TRAM
signal downstream TLR4, activating IRF3. TLR7 and TLR9 activate NF-κB and IRF7 via MyD88. NF-κB activation leads to proinﬂammatory
cytokines production, such as TNF-α and IL-12, whereas IRFs are required for type I IFN gene transcription.
modulatetheimmune response againstT. cruziwillbeofcri-
tical relevance for vaccine development against this impor-
tant human parasite.
6. Vaccinationagainst
Trypanosoma cruzi Infectiona
The strong speciﬁc immune response developed in most
hosts following T. cruzi infection does not eliminate the par-
asite, and parasite persistence is considered to be the main
factor contributing to the late symptoms of Chagas disease.
Therefore, eliminating the parasite at the early stage (acute
phase) prevents parasite survival and may be an interesting
route to avoid chronic phase immunopathology. Prophylact-
ic vaccination would help to reduce or completely eliminate
theparasiteburdenandthusrepresentsadesirablemethodto
restrict the development of chronic symptoms of the disease.
Untilrecently,vaccinationwasnotconsideredacost-eﬀective
measureforcontainmentofthediseasetransmissionbecause
other methods of prevention would be simpler and cheaper.
Nevertheless, recent detailed analyses have proved that in-
deed vaccination can be cost eﬀective in a variety of scenar-
ios including the regions where the prevalence is as low as
1% by using a vaccine which the eﬃcacy was only 25% [61].
Based on that, future research programs should consider
these calculations to support this type of biotechnological
alternative.
Because CD4+ and CD8+ T cells are critical mediators of
the acquired immune response, over the past 20 years, we
and others have tested the hypothesis that non-antibody-
mediated cellular immune responses to the antigens ex-
pressedinthemammalianformsoftheparasitecouldindeed
be used for the purpose of vaccination. Using a mouse model
ofthedisease,weconﬁrmedthishypothesisbyinducingpro-
tective immunity against T. cruzi infection speciﬁcally medi-
ated by CD4+ Th1 and CD8+ Tc1 cells speciﬁc for antigens8 Journal of Parasitology Research
expressed by trypomastigotes and amastigotes of T. cruzi
(reviewed by [62–64]).
T. cruzi antigens recognized by immune sera from im-
mune or infected humans or animals served as the basis for
researchers to conduct studies using recombinant proteins.
These recombinant proteins included members of the large
trans-sialidase (TS) surface protein family expressed mainly
in the infective trypomastigote and amastigote forms of the
parasite.Thesecondgroupofgenesbelongedtothefamilyof
cysteine-proteases(cruzipain)expressedinallofthediﬀerent
formsoftheparasite.Otherantigensformedaheterogeneous
group including molecules such as the ﬂagellar calcium-
binding protein, paraﬂagellar rod protein-2, LYT-1 antigen,
ribosomal protein L7a-like protein, and KMP11, among
others (reviewed by [62, 63]).
To induce T. cruzi-speciﬁc T lymphocytes and protective
immunity against an experimental infection, several delivery
antigens were used successfully such recombinant proteins
mixed in the presence of distinct adjuvants, plasmid DNA,
recombinant viruses, and bacteria. Very recently, genetically
attenuated parasites have been also successfully generated for
the purpose of the development of an oral veterinary vaccine
[65]. Protective immune response in the mouse model was
measured by the reduction in acute phase parasitemia, tissue
parasitism, and mortality. In most cases, immunity elicited
by these antigens was associated with type I immune res-
ponse, generated by IFN-γ-producing CD4+ and/or CD8+
Tcells.Someofthemechanismsmediatingprotectiveimmu-
nity were investigated. Following intranasal immunization
with (TS) in the presence of the TLR9 activator CpG ODN,
the absence of CD4+ or CD8+ T cells renders the vaccinated
animals completely susceptible to infection. Because these
animals were genetically deﬁcient, these cells can be required
for the induction or the eﬀector phase of the immune res-
ponse, orboth. Similarly, CD8-deﬁcient micefailedto gener-
ate protection after immunization with native Par-2 protein
emulsiﬁed in CFA or recombinant adenovirus expressing TS
or ASP-2 genes [66, 67]. Upon plasmid immunization, the
depletionofeitherCD4+ orCD8+ Tcellscompletelyreversed
protective immunity, thus demonstrating a nonoverlapping
role for these two subpopulations [68, 69]. Following vacci-
nation with recombinant protein of ASP-2 in alum and CpG
ODN,onlydepletionofCD8+,butnotCD4 +,Tcellsreversed
protective immunity [70]. Finally, vaccination with a single
T. cruzi epitope, recognized by CD8+ T cells [71], elicited
a protective immune response using a heterologous prime-
boost strategy with recombinant adenovirus and vaccinia
v i r u s .T h e s ee x p e r i m e n t a ls y s t e m sf o u n dt y p e1C D 4 + and
CD8+ T cells to be necessary, conﬁrming the general para-
digm that type 1 CD4+ and CD8+ T cells do play a key role
in protective immunity. In agreement with this hypothesis,
recent observations have pointed to IFN-γ as a critical med-
iator of the protective immune response [72]. Also relevant
is the fact that protective T cells can be long lived and stable
and display a phenotype of eﬀector memory T cells [73, 74].
Another recently added information that might be of general
importance for vaccine development has been the fact that
the target of these protective CD8+ T cells is not only the
immune-dominant epitopes, but they can also be subdom-
inant/cryptic T-cell epitopes [75, 76].
The question as to whether other cell types are also criti-
cal for the adaptive immunity induced by these recombinant
vaccines is currently being investigated. Still, noteworthy is
the fact that infection itself elicits strong type 1 immune res-
ponse, and it is not capable of clearing the parasite com-
pletely. This apparent contradiction suggests that there may
be qualitative diﬀerences between immune responses elicited
by infection or vaccination that are not revealed by the anal-
yses of the cytokine pattern. In fact, ongoing experiments
strongly argue that there are qualitative diﬀerences that ac-
count for the protective properties of the T cells expanded
after infection in genetically vaccinated mice (Vasconcelos,
unpublished results).
In spite of clear evidence that immunization with T. cruzi
antigens can provide protective immunity as measured by a
reduction in acute phase parasitemia, tissue parasitism, and
mortality, it is not clear whether immunization will lead to
either remission or a cure of the chronic phase symptoms of
the disease. To determine the role of immunization in reduc-
ing chronic phase disease symptoms, a number of experi-
ments using diﬀerent animal models must be performed. In
many of the models described above, tissue inﬂammation
and parasitism in the late chronic phase were signiﬁcantly re-
ducedfollowingprophylacticvaccination[69,77,78].There-
fore, it is possible that prophylactic vaccinations indeed halt
the development of the chronic phase immunopathologies.
Nevertheless, the most compelling evidence of a vaccine’s
abilitytoreducetheimmunopathologywasobtainedbyther-
apeutic immunization with T. cruzi genes encoding the TSA
and Tc24 genes [79]. Whether these results are reproducible
using diﬀerent combinations of mouse and parasite strains
remains to be seen.
In conclusion, in spite of the pessimism of certain re-
searchers, there are a number of experimental evidences that
support the fact that a vaccine against Chagas disease can be
obtained for veterinary use. This type of vaccine could have
a deﬁnitive impact on disease transmission. Whether this
knowledge can be translated into a vaccine for a human use
will still require considerable body of experimental and clin-
ical studies [80].
7. TLRs andthe Development of New Adjuvants
Understanding how pathogens initiate and direct immune
responses can provide useful perspectives for vaccine de-
velopment. In fact, in the last twenty years, the increasing
knowledge of the cellular and molecular mechanisms by
whichinnateimmunitysignalingtriggersparticularrespons-
es from APCs has allowed the design of new deﬁned adju-
vants. For example, monophosphoryl lipid A (MPL) is a
detoxiﬁed lipid A derivative of lipopolysaccharide from Sal-
monella enterica, which acts as a TLR4 partial agonist. It
preferentially induces the TRAM/TRIF-signaling pathway
and, consequently, has lower toxicity when compared to LPS
but retains its adjuvant properties [81]. MPL adsorbed to
aluminium salts has been used as adjuvant in prophylactic
vaccines against diﬀerent infectious agents, including an an-
tihuman papillomavirus (HPV) vaccine approved in Aus-
tralia, Europe, and the USA for the prevention of cervicalJournal of Parasitology Research 9
cancer[82].Therefore,researchfocusedontheidentiﬁcation
and characterization of PAMPs from T. cruzi,a sw e l la sf r o m
other pathogens, may provide us with new TLR agonists,
which combined to known adjuvant molecules will allow the
creation of a new generation of vaccines, which will be able,
for example, to direct the immune response toward a do-
minant Th1 proﬁle (required for protection against intra-
cellular pathogens) and will be endowed with long-lasting
immunologicalmemory.TLRagonistsmayalsobeemployed
not only in prophylaxis but also in therapeutic approaches.
This fascinating subject is however beyond the scope of the
present review and has recently been discussed in detail by
other authors [13, 83].
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